ARS Pharmaceuticals (NASDAQ:SPRY) PT Raised to $13.00

ARS Pharmaceuticals (NASDAQ:SPRY) had its price objective increased by analysts at Wedbush from $5.00 to $13.00 in a report issued on Monday, MarketBeat Ratings reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price objective would indicate a potential upside of 207.33% from the company’s current price.

Other research analysts have also issued reports about the company. William Blair lowered ARS Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 20th. Leerink Partnrs cut ARS Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 21st. Finally, SVB Leerink cut ARS Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 21st.

ARS Pharmaceuticals Stock Performance

SPRY opened at $4.23 on Monday. ARS Pharmaceuticals has a 52 week low of $2.55 and a 52 week high of $9.65. The business has a fifty day simple moving average of $4.42 and a 200-day simple moving average of $6.00.

Insider Transactions at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $7.71, for a total value of $771,000.00. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at $1,621,767.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Alexander A. Fitzpatrick bought 40,000 shares of the business’s stock in a transaction on Thursday, September 28th. The shares were bought at an average cost of $3.62 per share, with a total value of $144,800.00. Following the purchase, the insider now directly owns 42,969 shares in the company, valued at $155,547.78. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Laura Shawver sold 100,000 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $7.71, for a total transaction of $771,000.00. Following the sale, the director now directly owns 210,346 shares in the company, valued at $1,621,767.66. The disclosure for this sale can be found here. Over the last three months, insiders acquired 6,490,000 shares of company stock worth $31,575,800. Company insiders own 35.60% of the company’s stock.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of SPRY. Tower Research Capital LLC TRC purchased a new position in shares of ARS Pharmaceuticals during the 2nd quarter valued at $64,000. Wells Fargo & Company MN bought a new stake in ARS Pharmaceuticals in the second quarter worth $64,000. Teacher Retirement System of Texas bought a new stake in ARS Pharmaceuticals in the second quarter worth $69,000. Arizona State Retirement System bought a new stake in ARS Pharmaceuticals in the second quarter worth $71,000. Finally, Brendel Financial Advisors LLC bought a new stake in ARS Pharmaceuticals in the third quarter worth $72,000. 57.41% of the stock is currently owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis.